MDGL Stock Forecast: Madrigal Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 19 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. hold a median 12-month price target of $660 — +74.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 79 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Madrigal Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (95): Analysts have, on balance, been raising their forecasts.
Accruals (20): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MDGL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MDGL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +74.2% from it.
Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Nov 2026 | Canaccord Genuity | Maintains | Buy | $612 → $633 |
| 4 Nov 2026 | Truist Securities | Reiterates | Buy | $709 → $743 |
| 3 Nov 2026 | Citigroup | Maintains | Buy | $725 → $760 |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Buy | $704 |
| 23 Sept 2026 | Citigroup | Initiates | Buy | $725 |
| 4 Aug 2026 | Wolfe Research | Upgrade | Outperform | $605 |
| 3 Aug 2026 | Barclays | Maintains | Overweight | $964 → $962 |
| 29 July 2026 | Canaccord Genuity | Maintains | Buy | $578 → $587 |
| 27 July 2026 | Wells Fargo | Initiates | Overweight | $685 |
| 11 June 2026 | B of A Securities | Maintains | Neutral | $550 → $542 |
| 13 May 2026 | Truist Securities | Maintains | Buy | — |
| 7 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 7 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Feb 2026 | B of A Securities | Maintains | Neutral | — |
| 28 Jan 2026 | Barclays | Initiates | Overweight | — |
| 20 Jan 2026 | Citizens | Maintains | Market Outperform | — |
| 19 Dec 2025 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2025 | B. Riley Securities | Maintains | Buy | — |
| 21 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MDGL.
This page is one stock. Monday covers all of them.
MDGL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MDGL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Madrigal Pharmaceuticals, Inc. returned −30.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MDGL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 6.4×
- Price / book
- 14.6×
- EV / EBITDA
- —
Cheaper than 17% of US stocks
Cheaper than 5% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 89.0%
- Operating margin
- −10.7%
- Net margin
- —
Higher than 96% of US stocks
Higher than 26% of US stocks
- Return on equity
- −24.8%
- Return on assets
- −6.8%
- Dividend yield
- —
Higher than 30% of US stocks
Higher than 30% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Madrigal Pharmaceuticals, Inc. has a market value of $9.2B and an enterprise value of $8.6B.
Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 71.2% year on year.
Net income over the same four quarters: −$325.1M, a −25.3% net margin.
Diluted earnings per share, trailing twelve months: −$12.89.
Free cash flow in the twelve months to 30 June 2026: −$209.3M.
forward P/E: 38.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Madrigal Pharmaceuticals, Inc. employs 915 people — $1.4M of revenue per employee.
Data provided by Twelve Data
MDGL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MDGL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Madrigal Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MDGL
What is the MDGL stock price forecast for 2026-2027?
The 19 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. have a median 12-month price target of $660, with estimates ranging from $479 to $962. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MDGL stock a buy right now?
Of the 19 analysts covering Madrigal Pharmaceuticals, Inc., 18 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Madrigal Pharmaceuticals, Inc. 79 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MDGL?
As at 21 Nov 2026, Madrigal Pharmaceuticals, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).
Will MDGL stock go up?
No one can know that. What the data says: the median 12-month target from 19 analysts implies +74.2% from the last close, and Ticker Nerd's factor model ranks Madrigal Pharmaceuticals, Inc. 79 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MDGL stock forecast for 2030?
No analyst covering Madrigal Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $479 to $962 over the next 12 months.
How has MDGL stock performed over the past year?
Madrigal Pharmaceuticals, Inc. returned -30.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Madrigal Pharmaceuticals, Inc. do?
Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead product, Rezdiffra, is a once-daily oral therapy designed to address the underlying biology of MASH in adults with moderate to advanced liver fibrosis.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead product, Rezdiffra, is a once-daily oral therapy designed to address the underlying biology of MASH in adults with moderate to advanced liver fibrosis. The company’s current business is centered on liver disease, with a commercial presence supported by medical affairs, patient support, and market access activities. Madrigal Pharmaceuticals Inc. also maintains research and clinical development efforts around thyroid hormone receptor-beta science, reinforcing its role as a specialist company in hepatology and metabolic medicine. Based in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals Inc. serves a focused segment of the biopharmaceutical market that targets chronic liver and metabolic disorders.
CEO Mr. William J. Sibold · 915 employees · United States · https://www.madrigalpharma.com